Spyre Therapeutics Inc
NASDAQ:SYRE

Watchlist Manager
Spyre Therapeutics Inc Logo
Spyre Therapeutics Inc
NASDAQ:SYRE
Watchlist
Price: 15.07 USD 1.96% Market Closed
Market Cap: 908.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

SYRE Price Targets Summary
Spyre Therapeutics Inc

Wall Street analysts forecast SYRE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SYRE is 55.65 USD with a low forecast of 27.27 USD and a high forecast of 74.55 USD.

SYRE Lowest Forecast
Wall Street Target
27.27 USD
81% Upside
SYRE Average Forecast
Wall Street Target
55.65 USD
269% Upside
SYRE Highest Forecast
Wall Street Target
74.55 USD
395% Upside
Lowest
Price Target
27.27 USD
81% Upside
Average
Price Target
55.65 USD
269% Upside
Highest
Price Target
74.55 USD
395% Upside
Spyre Therapeutics Inc Competitors:
Price Targets
A
ARMP
Armata Pharmaceuticals Inc
282% Upside
300009
Anhui Anke Biotechnology Group Co Ltd
28% Upside
J
7774
Japan Tissue Engineering Co Ltd
121% Upside
HALO
Halozyme Therapeutics Inc
30% Upside
A
ARMP
Armata Pharmaceuticals Inc
282% Upside
300009
Anhui Anke Biotechnology Group Co Ltd
28% Upside
J
7774
Japan Tissue Engineering Co Ltd
121% Upside
HALO
Halozyme Therapeutics Inc
30% Upside
CPRX
Catalyst Pharmaceuticals Inc
42% Upside
LTRN
Lantern Pharma Inc.
570% Upside
COV
Covalon Technologies Ltd
66% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
56% Upside

Revenue
Forecast

Revenue Estimate
Spyre Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Spyre Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Spyre Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-96%
Average Miss
What are analyst estimates?

See Also

Summary
SYRE intrinsic value, competitors valuation, and company profile.
DCF Valuation
SYRE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SYRE stock valuation using valuation multiples.
Wall Street Estimates
SYRE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SYRE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SYRE's stock price target?
Price Target
55.65 USD

According to Wall Street analysts, the average 1-year price target for SYRE is 55.65 USD with a low forecast of 27.27 USD and a high forecast of 74.55 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.